Roche launches R&D Institute in France
pharmafile | June 24, 2011 | News story | Research and Development | Roche, translational research
Roche has launched a new R&D Institute in France, furthering its links with academic centres in the country.
The Institute, which will sit within Roche’s Pharma Research and Early Development (pRED) unit, will be dedicated to collaborative translational research and medicine.
Roche said the pRED French R&D Institute would serve as an entry-point for academic collaborations in France in areas of mutual interest, including oncology, neurosciences, metabolism, inflammation, virology, translational research and toxicology.
The Institute adds to a number of collaborative ties in France, which includes its work with the Curie Institute for biomarkers in triple-negative breast cancer and with the Pasteur Institute, MIRCEN and ICM, for the development of new imaging markers in Alzheimer’s disease.
It also furthers Roche’s ongoing collaborations across the world, adding to similar hubs in Singapore, its native Switzerland and the Netherlands.
Jean-Jacques Garaud, global head of pRED at Roche, said: “We are committed to establishing robust collaborations in France, which ranks among the leading nations in life-science research, with internationally recognised experts and a fantastic innovation potential.
“The pRED French R&D Institute will enable us to work hand-in-hand with France’s world-class scientists in a common objective: accelerating the translation of early scientific discoveries into innovative and personalised treatments for patients,” he added.
Sophie Kornowski-Bonnet, head of Roche France, said its objective was also to hasten the development of new therapies for patients.
“Through this network of strategic collaborations with best-in-class French academic centres, we, at Roche, intend to leverage the fantastic innovation potential of France and progress towards our mission to deepen our understanding of life sciences,” she said.
Ben Adams
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
